Search Results

Kriya Therapeutics, Inc. announced three presentations at the Association for Research in Vision and Ophthalmology Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Apellis Pharmaceuticals, Inc. announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting to be held May 5 - 9 in Seattle.

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.

Skye Bioscience, Inc. today announced that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington.

Krystal Biotech, Inc., a commercial-stage biotechnology company, announced that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington.

Bausch + Lomb Corporation today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024.

Alimera Sciences, Inc. announced it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology conference, scheduled in Seattle, WA. from May 5 - 9 and Retina World Congress scheduled in Fort Lauderdale, FL. from May 9 - 13.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

Ocugen, Inc. announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa, OCU410 for the treatment of geographic atrophy, and OCU410ST for the treatment of Stargardt disease at The Association for Research in Vision and Ophthalmology 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

Ocugen, Inc. announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa, OCU410 for the treatment of geographic atrophy, and OCU410ST for the treatment of Stargardt disease at The Association for Research in Vision and Ophthalmology 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.